Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

44 citing papers in PubMed.

1. Nanoadjuvant-integrated organic biomaterials for immune engineering: Mechanisms, design strategies, and translational applications.Materials today. Bio · 2026
   Review
2. Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities.Journal for immunotherapy of cancer · 2025
   Article
3. Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.Nature protocols · 2024
   Review
4. The emerging field of oncolytic virus-based cancer immunotherapy.Trends in cancer · 2023
   Review
5. Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine.Frontiers in bioengineering and biotechnology · 2023
   Article
6. Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model.Frontiers in immunology · 2022
   Article
7. Using a Prime-Boost Vaccination Strategy That Proved Effective for High Resolution Epitope Mapping to Characterize the Elusive Immunogenicity of Survivin.Cancers · 2021
   Article
8. Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors.Saudi journal of biological sciences · 2021
   Article
9. Viroimmunotherapy for breast cancer: promises, problems and future directions.Cancer gene therapy · 2021
   Review
10. Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis.Scientific reports · 2021
    Article
11. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.Nature communications · 2021
    Article
12. In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity.Journal for immunotherapy of cancer · 2021
    Article
13. The Role of Vesicular Stomatitis Virus Matrix Protein in Autophagy in the Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2021
    Article
14. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.International journal of molecular sciences · 2020
    Article
15. Optimizing oncolytic virotherapy in cancer treatment.Nature reviews. Drug discovery · 2019
    Review
16. Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity.The Journal of clinical investigation · 2019
    Article
17. Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice.Journal of virology · 2018
    Article
18. Oncolytic viruses and immunity.Current opinion in immunology · 2018
    Review
19. Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2018
    Article
20. Development and applications of oncolytic Maraba virus vaccines.Oncolytic virotherapy · 2018
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors.

Funding

Abstract

Indexed as